Highlights from the Discussion

McGuire W.P. , Brady M.F. , Ozols R.F. . The Gynecologic Oncology Group experience in ovarian cancer. Ann Oncol. 1999; 10(suppl 1): 29–34.

Dizon D. , Spriggs DR Recurrent ovarian cancer. In Penalver M. , Angioli R. , Benedetti-Panici P , eds. Principles and Practice of Chemotherapy for Gynecologic Neoplasms: Current Therapy/Novel Approaches. Marcel Dekker, Inc. In Press.

Barakat R.R. , Almadrones L. , Venkatraman E.S. . A phase II trial of intraperitoneal cisplatin and etoposide as consolidation therapy in patients with stage IIIV epithelial ovarian cancer following negative surgical assessment. Gynecol Oncol. 1998; 69: 17–22.

Gershenson D.M. , Mitchell M.E. , Atkinson N. . The effect of prolonged cisplatin-based chemotherapy on progression-free survival in patients with optimal epithelial ovarian cancer: “maintenance therapy “ reconsidered. Gynecol Oncol. 1992; 47: 7–13.

Bolis G. , Scarfone G. , Tateo S. . Response and toxicity to topotecan in sensitive ovarian cancer cases with small residual disease after first-line treatment with carboplatin and paclitaxel. Gynecol Oncol. 2001; 80: 13–15.

Blackledge G. , Lawton F , Redman C. . Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials. Br J Cancer. 1989; 59: 650–653.

Gore M.E. , Fryatt I. , Wiltshaw E. . Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol Oncol. 1990; 36: 207–211.

Markman M. , Rothman R. , Hakes T. . Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol. 1991; 9: 389–393.

Kavanagh J. , Tresukosol D. , Edwards C. . Carboplatin reinduction after taxane in patients with platinum-refractory epithelial ovarian cancer. J Clin Oncol. 1995; 13: 1584–1588.

Colombo N. , Marzola M. , Parma G. . Paclitaxel vs CAP (cyclophosphamide, Adriamycin, cisplatin) in recurrent platinum-sensitive ovarian cancer: a randomized phase II study. Proc Annu Meet Am Soc Clin Oncol. 1996; 15: 279, Abstract 751.

McGuire W.P. , Blessing J.A. , Bookman M.A. . Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 2000; 18: 1062–1067.

Bookman M. . Extending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line chemotherapy. Oncologist. 1999; 4: 87–94.

Alberts D.S. . Treatment of refractory and recurrent ovarian cancer. Semin Oncol. 1999; 26: 8–14.

Markman M. , Kennedy A. , Webster K. . Clinical features of hypersensitivity reactions to carboplatin. J Clin Oncol. 1999; 17: 1141–1145.

Cesano A. , Lane S.R. , Poulin R. . Stabilization of disease as a useful predictor of survival following second-line chemotherapy in small cell lung cancer and ovarian cancer patients. Int J Oncol. 1999; 15: 1233–1238.

Gordon A.N. , Fleagle J.T. , Guthrie D. . Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol. 2001; 19: 3312–3322.

Armstrong D. , O'Reilly S. . Clinical guidelines for managing topotecan-related hematologic toxicity. Oncologist. 1998; 3: 4–10.